In the present study, lipiodol has not shown correlation with the survival outcomes associated with the combination treatment, but we find some evidence that increased lipiodol deposition may increase the anti-VEGF activity of sorafenib as lipiodol retention increases the tumor vascular permeability of the drug and hence, increased anti-VEGF activity may be the reason behind the survival benefits. This evidence concerns the gene VEGFA and neoplasm.